Deltex Medical Group plc is a United Kingdom-based medical device company. The Company develops and manufactures specialist hemodynamics monitoring devices. The Company's TrueVue platform offers three monitoring technologies, such as Oesophageal Doppler Monitoring (ODM+), Pulse Pressure Waveform Analysis (PPWA) and High Definition Impedance CardioGraphy (HD-ICG). ODM+ guides fluid and drug interventions in real-time and keeps surgical patients in a haemodynamic state. PPWA uses the researched pulse pressure wave algorithm, which is available to derive haemodynamic parameters, calibrated from the Doppler. HD-ICG provides continuous and sensitive measurements of cardiac output and other haemodynamic parameters. The Company’s applications include COVID-19 critical care, surgery, acute kidney injury, enhanced recovery and paediatric. Its commercial activities are around three divisions: the United Kingdom, the United States and International.